LHN - Stock Analyst Research

Target Price* 0.39
Recommendation BUY
Market Cap*-
Publication Date8 Mar 2024

*At the time of publication

LHN Limited - Another growth driver emerges

  • In the 1Q24 update, no financials were provided, but LHN reiterated that the occupancy of their portfolio of assets (industrial, commercial, co-living) is over 90%. The two major projects, 55 Tuas South and GSM Building, are proceeding as scheduled.
  • On 25 January, LHN secured two sites to provide accommodation for 700 public sector healthcare professionals (mainly nurses and allied health professionals). Operations will commence in 2H24. We believe LHN’s advantage in securing this project is its operational experience in the co-living sector.
  • We maintain our forecast and BUY recommendation. Our target price of S$0.39 is unchanged. We peg our valuations to 6.5x FY24e P/E, while the industry is trading around 13x. Earnings visibility has improved as planned projects are underway and occupancy rates remain vibrant. We view the healthcare accommodation project as a new growth driver. Margins are unclear, but the project is capital light as the authorities provide the premises. Eleven more potential sites may be tendered out.

 

Key Highlights

 

  1. Strong occupancy over 90%. All three assets—industrial, commercial, and coliving—enjoyed over 90% occupancy as of 31 December 2023. The two-week-old and 15th co-living property, Coliwoo Hotel Pasir Panjang, has already achieved 60% occupancy. A larger proportion of tenants are foreigners, mainly professionals and students. The average length of stay is 6 to 9 months. The 15 industrial properties are also 90% occupied with stable rents due to the current demand and supply conditions.

 

  1. Major planned projects are proceeding well. The two upcoming major projects 55 Tuas South and GSM building are developing as scheduled. 55 Tuas was purchased for S$21mn and to be developed into a 49-unit food factory or central kitchen for sale. Completion by August 2024. GSM Building was purchased for S$80mn and can be developed into 187 rooms for co-living with 1 floor commercial. Possible commencement is 2Q25.

 

  1. A new growth driver emerges. On 25 January, LHN secured the contract with MOH Holdings (holding company for Singapore’s public healthcare institutions) to design, retrofit, and operate two lodging facilities for healthcare professionals at 100 Ulu Pandan Road and 60 Boundary Close. It will house 700 healthcare professionals and start operations 2H24. LHN secured two of the five tendered sites. A joint venture between The Assembly Place and the TS Group secured the three other sites to house 1,180 healthcare professionals. There is potential for another 11 sites once MOH monitors the usage of the current five sites. Around 58,000 healthcare professionals (nurses, allied health professionals, and support care) operate hospitals, clinics, and eldercare centres in 2022. The Ministry of Health estimates that this will need to grow to 82,000 by 2030.

 

 

Maintain BUY with unchanged TP of S$0.39

Our valuations are pegged to 6.5x FY24e P/E, while the industry trades around 13x. LHN is trading at 5.6x PE, a 37% discount to its book value of S$0.53.

About the author

Paul Chew
Head of Research
Phillip Securities Research Pte Ltd

Paul has 20 years of experience as a fund manager and sell-side analyst. During his time as fund manager, he has managed multiple funds and mandates including capital guaranteed, dividend income, renewable energy, single country and regionally focused funds.

He graduated from Monash University and had completed both his Chartered Financial Analyst and Australian CPA programme.

Latest Reports

Contact us to Open an Account

Need Assistance? Share your Details and we’ll get back to you

IMPORTANT INFORMATION

This material is provided by Phillip Capital Management (S) Ltd (“PCM”) for general information only and does not constitute a recommendation, an offer to sell, or a solicitation of any offer to invest in any of the exchange-traded fund (“ETF”) or the unit trust (“Products”) mentioned herein. It does not have any regard to your specific investment objectives, financial situation and any of your particular needs. You should read the Prospectus and the accompanying Product Highlights Sheet (“PHS”) for key features, key risks and other important information of the Products and obtain advice from a financial adviser (“FA“) pursuant to a separate engagement before making a commitment to invest in the Products. In the event that you choose not to obtain advice from a FA, you should assess whether the Products are suitable for you before proceeding to invest. A copy of the Prospectus and PHS are available from PCM, any of its Participating Dealers (“PDs“) for the ETF, or any of its authorised distributors for the unit trust managed by PCM.  

An ETF is not like a typical unit trust as the units of the ETF (the “Units“) are to be listed and traded like any share on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Listing on the SGX-ST does not guarantee a liquid market for the Units which may be traded at prices above or below its NAV or may be suspended or delisted. Investors may buy or sell the Units on SGX-ST when it is listed. Investors cannot create or redeem Units directly with PCM and have no rights to request PCM to redeem or purchase their Units. Creation and redemption of Units are through PDs if investors are clients of the PDs, who have no obligation to agree to create or redeem Units on behalf of any investor and may impose terms and conditions in connection with such creation or redemption orders. Please refer to the Prospectus of the ETF for more details.  

Investments are subject to investment risks including the possible loss of the principal amount invested. The purchase of a unit in a fund is not the same as placing your money on deposit with a bank or deposit-taking company. There is no guarantee as to the amount of capital invested or return received. The value of the units and the income accruing to the units may fall or rise. Past performance is not necessarily indicative of the future or likely performance of the Products. There can be no assurance that investment objectives will be achieved.  

Where applicable, fund(s) may invest in financial derivatives and/or participate in securities lending and repurchase transactions for the purpose of hedging and/or efficient portfolio management, subject to the relevant regulatory requirements. PCM reserves the discretion to determine if currency exposure should be hedged actively, passively or not at all, in the best interest of the Products.  

The regular dividend distributions, out of either income and/or capital, are not guaranteed and subject to PCM’s discretion. Past payout yields and payments do not represent future payout yields and payments. Such dividend distributions will reduce the available capital for reinvestment and may result in an immediate decrease in the net asset value (“NAV”) of the Products. Please refer to <www.phillipfunds.com> for more information in relation to the dividend distributions.  

The information provided herein may be obtained or compiled from public and/or third party sources that PCM has no reason to believe are unreliable. Any opinion or view herein is an expression of belief of the individual author or the indicated source (as applicable) only. PCM makes no representation or warranty that such information is accurate, complete, verified or should be relied upon as such. The information does not constitute, and should not be used as a substitute for tax, legal or investment advice.  

The information herein are not for any person in any jurisdiction or country where such distribution or availability for use would contravene any applicable law or regulation or would subject PCM to any registration or licensing requirement in such jurisdiction or country. The Products is not offered to U.S. Persons. PhillipCapital Group of Companies, including PCM, their affiliates and/or their officers, directors and/or employees may own or have positions in the Products. Any member of the PhillipCapital Group of Companies may have acted upon or used the information, analyses and opinions herein before they have been published. 

This advertisement has not been reviewed by the Monetary Authority of Singapore.  

 

Phillip Capital Management (S) Ltd (Co. Reg. No. 199905233W)  
250 North Bridge Road #06-00, Raffles City Tower ,Singapore 179101 
Tel: (65) 6230 8133 Fax: (65) 65383066 www.phillipfunds.com